Total
0
Shares
PolyNovo (ASX:PNV) dispatches first NovoSorb BTM order in Europe
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical device company PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development
  • Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations
  • He will focus on quickly growing a research and development team to capture and commercialise the many business developments and new product opportunities
  • On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share

PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development.

Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations.

Previously, he has worked as product development manager, operations director, research and development director and Chief Technology Officer at SDI, a medical devices company that specialises in manufacturing dental materials.

Joshua will focus on quickly growing a research and development team to
capture and commercialise the many business developments and new product opportunities.

His role is to lead the innovation strategy and research and development activities and to develop the future product portfolio for PolyNovo.

"This is a very exciting and significant appointment that will spearhead the
building of a world-class research and development team befitting the company’s market capitalisation," Chairman David Williams said.

Managing Director Paul Brennan says the company will continue to invest in the expansion of its research and development team.

"Joshua will be recruiting additional scientists to bolster the team and accelerate our pipeline of new products," he added.

On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share.

PNV by the numbers
More From The Market Herald
Gabon-focussed iron ore company Genmin (ASX:GEN) lists on ASX

" Argenica Therapeutics (ASX:AGN) lists on ASX

Argenica Therapeutics (AGN) has finished its first day of trade on the ASX, following a well supported initial public offering.
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.